Journal article
Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study
BMC cancer, Vol.18(1), pp.770-770
2018
DOI: 10.1186/s12885-018-4686-x
PMCID: PMC6066931
PMID: 30060745
Abstract
BACKGROUND: There has been interest in the potential benefit of vitamin D (VD) to improve breast cancer outcomes. Pre-clinical studies suggest VD enhances chemotherapy-induced cell death. Vitamin D deficiency was associated with not attaining a pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC) for operable breast cancer. We report the impact of VD on pCR and survival in an expanded cohort.METHODS: Patients from Iowa and Montpellier registries who had serum VD level measured before or during NAC were included. Vitamin D deficiency was defined as < 20 ng/mL. Pathological complete response was defined as no residual invasive disease in the breast and lymph nodes. Survival was defined from the date of diagnosis to the date of relapse (PFS) or date of death (OS).RESULTS: The study included 327 women. Vitamin D deficiency was associated with the odds of not attaining pCR (p = 0.04). Fifty-four patients relapsed and 52 patients died. In multivariate analysis, stage III disease, triple-negative (TN) subtype and the inability to achieve pCR were independently associated with inferior survival. Vitamin D deficiency was not significantly associated with survival in the overall sample; however a trend was seen in the TN (5-years PFS 60.4% vs. 72.3%, p = 0.3), and in the hormone receptor positive /human epidermal growth factor receptor 2 negative (HER2-) subgroups (5-years PFS 89% vs 78%, p = 0.056).CONCLUSION:Vitamin D deficiency is associated with the inability to reach pCR in breast cancer patients undergoing NAC.
Details
- Title: Subtitle
- Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study
- Creators
- Marie Viala - ICM PartnersAkiko Chiba - Wake Forest UniversitySimon Thèzenas - ICM PartnersLaure Delmond - ICM PartnersPierre-Jean Lamy - Imagenome-labosud, Clinique BeauSoleil, Montpellier, France.Sarah Mott - HoldenMary Schroeder - University of IowaAlexandra Thomas - Wake Forest UniversityWilliam Jacot - ICM Partners
- Resource Type
- Journal article
- Publication Details
- BMC cancer, Vol.18(1), pp.770-770
- DOI
- 10.1186/s12885-018-4686-x
- PMID
- 30060745
- PMCID
- PMC6066931
- NLM abbreviation
- BMC Cancer
- ISSN
- 1471-2407
- eISSN
- 1471-2407
- Publisher
- BioMed Central
- Grant note
- name: GEFLUC Languedoc-Roussillon
- Language
- English
- Date published
- 2018
- Academic Unit
- Pharmacy Practice and Science; Internal Medicine
- Record Identifier
- 9984366041502771
Metrics
11 Record Views